Mustafa Y Ahmed1, Barry A Chioza1, Anna Rajab1, Klaus Schmitz-Abe1, Aisha Al-Khayat1, Saeed Al-Turki1, Emma L Baple1, Michael A Patton1, Ali Y Al-Memar1, Matthew E Hurles1, Jennifer N Partlow1, R Sean Hill1, Gilad D Evrony1, Sarah Servattalab1, Kyriacos Markianos1, Christopher A Walsh1, Andrew H Crosby1, Ganeshwaran H Mochida2. 1. From Monogenic Molecular Genetics (M.Y.A., B.A.C., E.L.B., A.H.C.), University of Exeter Medical School, RILD Wellcome Wolfson Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter; Centre for Human Genetics (M.Y.A., B.A.C., E.L.B., M.A.P., A.H.C.), St. George's, University of London, UK; National Genetic Center (A.R.), Ministry of Health, Muscat, Sultanate of Oman; Division of Genetics and Genomics, Department of Medicine (K.S.-A., J.N.P., R.S.H., G.D.E., S.S., K.M., C.A.W., G.H.M.), Manton Center for Orphan Disease Research (K.S.-A., J.N.P., R.S.H., G.D.E., S.S., K.M., C.A.W., G.H.M.), and Howard Hughes Medical Institute (J.N.P., R.S.H., G.D.E., S.S., C.A.W.), Boston Children's Hospital; Departments of Pediatrics (K.S.-A., K.M., C.A.W., G.H.M.) and Neurology (C.A.W.), and Program in Biological and Biomedical Sciences (G.D.E.), Harvard Medical School, Boston; Program in Medical and Population Genetics (K.S.-A., K.M., C.A.W.), Broad Institute of MIT and Harvard University, Cambridge, MA; Department of Biology (A.A.-K.), College of Science, Sultan Qaboos University, Sultanate of Oman; Wellcome Trust Sanger Institute (S.A.-T., M.E.H.), Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Department of Neurology (A.Y.A.-M.), Atkinson Morley Wing, St. George's Hospital, London, UK; and Pediatric Neurology Unit (G.H.M.), Department of Neurology, Massachusetts General Hospital, Boston, MA. 2. From Monogenic Molecular Genetics (M.Y.A., B.A.C., E.L.B., A.H.C.), University of Exeter Medical School, RILD Wellcome Wolfson Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter; Centre for Human Genetics (M.Y.A., B.A.C., E.L.B., M.A.P., A.H.C.), St. George's, University of London, UK; National Genetic Center (A.R.), Ministry of Health, Muscat, Sultanate of Oman; Division of Genetics and Genomics, Department of Medicine (K.S.-A., J.N.P., R.S.H., G.D.E., S.S., K.M., C.A.W., G.H.M.), Manton Center for Orphan Disease Research (K.S.-A., J.N.P., R.S.H., G.D.E., S.S., K.M., C.A.W., G.H.M.), and Howard Hughes Medical Institute (J.N.P., R.S.H., G.D.E., S.S., C.A.W.), Boston Children's Hospital; Departments of Pediatrics (K.S.-A., K.M., C.A.W., G.H.M.) and Neurology (C.A.W.), and Program in Biological and Biomedical Sciences (G.D.E.), Harvard Medical School, Boston; Program in Medical and Population Genetics (K.S.-A., K.M., C.A.W.), Broad Institute of MIT and Harvard University, Cambridge, MA; Department of Biology (A.A.-K.), College of Science, Sultan Qaboos University, Sultanate of Oman; Wellcome Trust Sanger Institute (S.A.-T., M.E.H.), Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Department of Neurology (A.Y.A.-M.), Atkinson Morley Wing, St. George's Hospital, London, UK; and Pediatric Neurology Unit (G.H.M.), Department of Neurology, Massachusetts General Hospital, Boston, MA. ganesh.mochida@childrens.harvard.edu.
Abstract
OBJECTIVE: To identify the genetic cause of pontocerebellar hypoplasia type III (PCH3). METHODS: We studied the original reported pedigree of PCH3 and performed genetic analysis including genome-wide single nucleotide polymorphism genotyping, linkage analysis, whole-exome sequencing, and Sanger sequencing. Human fetal brain RNA sequencing data were then analyzed for the identified candidate gene. RESULTS: The affected individuals presented with severe global developmental delay and seizures starting in the first year of life. Brain MRI of an affected individual showed diffuse atrophy of the cerebrum, cerebellum, and brainstem. Genome-wide single nucleotide polymorphism analysis confirmed the linkage to chromosome 7q we previously reported, and showed no other genomic areas of linkage. Whole-exome sequencing of 2 affected individuals identified a shared homozygous, nonsense variant in the PCLO (piccolo) gene. This variant segregated with the disease phenotype in the pedigree was rare in the population and was predicted to eliminate the PDZ and C2 domains in the C-terminus of the protein. RNA sequencing data of human fetal brain showed that PCLO was moderately expressed in the developing cerebral cortex. CONCLUSIONS: Here, we show that a homozygous, nonsense PCLO mutation underlies the autosomal recessive neurodegenerative disorder, PCH3. PCLO is a component of the presynaptic cytoskeletal matrix, and is thought to be involved in regulation of presynaptic proteins and synaptic vesicles. Our findings suggest that PCLO is crucial for the development and survival of a wide range of neuronal types in the human brain.
OBJECTIVE: To identify the genetic cause of pontocerebellar hypoplasia type III (PCH3). METHODS: We studied the original reported pedigree of PCH3 and performed genetic analysis including genome-wide single nucleotide polymorphism genotyping, linkage analysis, whole-exome sequencing, and Sanger sequencing. Human fetal brain RNA sequencing data were then analyzed for the identified candidate gene. RESULTS: The affected individuals presented with severe global developmental delay and seizures starting in the first year of life. Brain MRI of an affected individual showed diffuse atrophy of the cerebrum, cerebellum, and brainstem. Genome-wide single nucleotide polymorphism analysis confirmed the linkage to chromosome 7q we previously reported, and showed no other genomic areas of linkage. Whole-exome sequencing of 2 affected individuals identified a shared homozygous, nonsense variant in the PCLO (piccolo) gene. This variant segregated with the disease phenotype in the pedigree was rare in the population and was predicted to eliminate the PDZ and C2 domains in the C-terminus of the protein. RNA sequencing data of human fetal brain showed that PCLO was moderately expressed in the developing cerebral cortex. CONCLUSIONS: Here, we show that a homozygous, nonsense PCLO mutation underlies the autosomal recessive neurodegenerative disorder, PCH3. PCLO is a component of the presynaptic cytoskeletal matrix, and is thought to be involved in regulation of presynaptic proteins and synaptic vesicles. Our findings suggest that PCLO is crucial for the development and survival of a wide range of neuronal types in the human brain.
Authors: C Cases-Langhoff; B Voss; A M Garner; U Appeltauer; K Takei; S Kindler; R W Veh; P De Camilli; E D Gundelfinger; C C Garner Journal: Eur J Cell Biol Date: 1996-03 Impact factor: 4.492
Authors: Clarissa L Waites; Sergio A Leal-Ortiz; Nathan Okerlund; Hannah Dalke; Anna Fejtova; Wilko D Altrock; Eckart D Gundelfinger; Craig C Garner Journal: EMBO J Date: 2013-02-12 Impact factor: 11.598
Authors: Clarissa L Waites; Sergio A Leal-Ortiz; Till F M Andlauer; Stefan J Sigrist; Craig C Garner Journal: J Neurosci Date: 2011-10-05 Impact factor: 6.167
Authors: Simone A Fietz; Robert Lachmann; Holger Brandl; Martin Kircher; Nikolay Samusik; Roland Schröder; Naharajan Lakshmanaperumal; Ian Henry; Johannes Vogt; Axel Riehn; Wolfgang Distler; Robert Nitsch; Wolfgang Enard; Svante Pääbo; Wieland B Huttner Journal: Proc Natl Acad Sci U S A Date: 2012-07-02 Impact factor: 11.205
Authors: Frédéric Léveillé; Sofia Papadia; Michael Fricker; Karen F S Bell; Francesc X Soriano; Marc-André Martel; Clare Puddifoot; Marlen Habel; David J Wyllie; Chrysanthy Ikonomidou; Aviva M Tolkovsky; Giles E Hardingham Journal: J Neurosci Date: 2010-02-17 Impact factor: 6.167
Authors: Ganeshwaran H Mochida; Vijay S Ganesh; Maria I de Michelena; Hugo Dias; Kutay D Atabay; Katie L Kathrein; Hsuan-Ting Huang; R Sean Hill; Jillian M Felie; Daniel Rakiec; Danielle Gleason; Anthony D Hill; Athar N Malik; Brenda J Barry; Jennifer N Partlow; Wen-Hann Tan; Laurie J Glader; A James Barkovich; William B Dobyns; Leonard I Zon; Christopher A Walsh Journal: Nat Genet Date: 2012-09-30 Impact factor: 38.330
Authors: Hanna Regus-Leidig; Corinna Ott; Martina Löhner; Jenny Atorf; Michaela Fuchs; Tina Sedmak; Jan Kremers; Anna Fejtová; Eckart D Gundelfinger; Johann H Brandstätter Journal: PLoS One Date: 2013-08-06 Impact factor: 3.240
Authors: Frauke Ackermann; Kay Oliver Schink; Christine Bruns; Zsuzsanna Izsvák; F Kent Hamra; Christian Rosenmund; Craig Curtis Garner Journal: Elife Date: 2019-05-10 Impact factor: 8.140
Authors: Ekaterina L Ivanova; Frédéric Tran Mau-Them; Saima Riazuddin; Kimia Kahrizi; Vincent Laugel; Elise Schaefer; Anne de Saint Martin; Karen Runge; Zafar Iqbal; Marie-Aude Spitz; Mary Laura; Nathalie Drouot; Bénédicte Gérard; Jean-François Deleuze; Arjan P M de Brouwer; Attia Razzaq; Hélène Dollfus; Muhammad Zaman Assir; Patrick Nitchké; Maria-Victoria Hinckelmann; Hilger Ropers; Sheikh Riazuddin; Hossein Najmabadi; Hans van Bokhoven; Jamel Chelly Journal: Am J Hum Genet Date: 2017-08-17 Impact factor: 11.025
Authors: Jijun Wan; Janos Steffen; Michael Yourshaw; Hafsa Mamsa; Erik Andersen; Sabine Rudnik-Schöneborn; Kate Pope; Katherine B Howell; Catriona A McLean; Andrew J Kornberg; Jörg Joseph; Paul J Lockhart; Klaus Zerres; Monique M Ryan; Stanley F Nelson; Carla M Koehler; Joanna C Jen Journal: Brain Date: 2016-11-01 Impact factor: 13.501
Authors: Rebecca Lazensky; Margaret E Hunter; David Moraga Amador; Basima Al-Khedery; Fahong Yu; Cathy Walsh; Matthew A Gitzendanner; Katie Tripp; Michael T Walsh; Nancy D Denslow Journal: PLoS One Date: 2020-07-02 Impact factor: 3.240
Authors: Kritika Krishnamurthy; Amilcar A Castellano-Sanchez; Christopher A Febres-Aldana; Jyotsna Kochiyil; Carole Brathwaite; Robert J Poppiti Journal: Case Rep Pediatr Date: 2019-12-10